Traveling During COVID-19: How Two Offices Combined Their Expertise to Properly Advise FNL in the Heat of a Pandemic
Thursday, August 25, 2022
An ounce of prevention is worth a pound of cure. Especially in the medical world, it’s far more effective and, often, more convenient to avoid an ailment entirely rather than to treat it. Occupational Health Services at Frederick National Laboratory has long championed this ideology, but the rise of the COVID-19 pandemic in March 2020 posed new challenges for prevention, especially for employees traveling.
Tuesday, August 23, 2022
Magic shows are a staple of children’s party entertainment. The sudden appearance of a cute bunny pulled from a hat or a flick of a card appearing at the top of the deck is enough to make any crowd go wild. However, for Andy Byrd, Ph.D., the thrill came from visiting his grandfather’s chemistry laboratory.
Thursday, August 18, 2022
The National Cancer Institute and Frederick National Laboratory for Cancer Research will hold the annual Technology Showcase on Wednesday, Sept. 7 in a hybrid format to welcome in-person attendees as well as remote participants from around the United States and the world. The event is scheduled from noon to 5:30 pm ET at the FNL’s Advanced Technology Research Facility in Frederick, Md.
Thursday, July 28, 2022
At the ripe old age of six, Vihaan Patel is a committed environmentalist. So it’s no surprise that he participated in—and won—the Environment, Health, and Safety (EHS) Directorate’s Paint the Drain competition earlier this year.
Biopharmaceutical Development Program Produces Personalized Anticancer Medicine for Young People with Cancer
Monday, July 25, 2022
Chimeric antigen receptor (CAR) T cell therapy is a hot topic in healthcare. Successfully used to treat certain aggressive blood cancers for about a decade now, CAR T cell therapy is capturing the growing interest of oncologists who would like to harness its power to use against other cancer types. At Frederick National Laboratory, the Biopharmaceutical Development Program—a specialized team manufacturing experimental biotherapeutics for NCI—is at the center of an effort to develop CAR T therapies that will expand cancer treatment options, particularly for pediatric malignancies.